ELVNEnliven Therapeutics, Inc.

$60.87

Who owns ELVN

163 institutions reported holding ELVN for 2026Q1, together 99% of the company, more than the 125 a quarter earlier.

163

Institutions reporting a position · as of 2026Q1 · up from 125 the quarter before

Shares held by institutions
62.4M

Shares held by institutions · 99% of the company · long US equity positions only, as reported on Form 13F

Reported value
$2.43B

Reported value · at 2026-03-31 prices, not today's

Top 5 holders
43%

Top 5 holders · of the whole company, between five filers

Details
Reporting quarter2026-03-31
2026Q1
Quarters on record
13
New positions
56
Positions exited
19
Added to
60
Reduced
31
Top 10 holdersof the company
62%
Institutional ownership by quarter, 2023Q1 to 2026Q1
QuarterFilersSharesReported value
2026Q116362.4M$2.43B
2025Q412562.4M$961M
2025Q313359.4M$1.22B
2025Q212359.4M$1.19B
2025Q112049.9M$984M
2024Q411249.6M$1.12B
2024Q310147.7M$1.22B
2024Q29248.3M$1.13B
2024Q17344.4M$780M
2023Q46239.0M$540M
2023Q36139.1M$534M
2023Q26339.1M$798M
2023Q14533.6M$735M
Largest reported holders, 2026Q1
HolderShares% of companyValue
ORBIMED ADVISORS LLC8.0M13%$312M
FMR LLC6.8M11%$268M
Polar Capital Holdings Plc5.1M8.1%$199M
BlackRock Inc.3.7M5.9%$144M
Commodore Capital LP3.3M5.2%$128M
Vestal Point Capital, LP3.3M5.2%$127M
VANGUARD GROUP INC2.9M4.6%$112M
Bellevue Group AG2.3M3.7%$91M
Fairmount Funds Management LLC1.9M3.0%$73M
CITADEL ADVISORS LLC1.7M2.8%$68M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…